|
業務類別
|
Biotechnology |
|
業務概覽
|
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs. |
| 公司地址
| 50 rue de Dijon, Daix, FRA, 21121 |
| 電話號碼
| +33 380447500 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inventivapharma.com |
| 員工數量
| 77 |
| Dr. Jason A. Campagna, M.D.,PhD |
President, Research and Development and Chief Medical Officer |
-- |
08/04/2026 |
| Mr. Jean Volatier |
Chief Financial Officer and Deputy General Manager |
美元 212.92K |
08/04/2026 |
| Mr. Andrew Obenshain |
Chief Executive Officer |
-- |
08/04/2026 |
| Ms. Martine Zimmermann, Pharm.D. |
Executive Vice President, Regulatory Affairs and Quality Assurance |
美元 149.50K |
08/04/2026 |
|
|
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
08/04/2026 |
| Dr. Mark Pruzanski, M.D. |
Chairman of the Board |
08/04/2026 |
| Dr. Annick Schwebig |
Independent Director |
08/04/2026 |
| Mr. G. Andre Turenne |
Independent Director |
08/04/2026 |
| Mr. Heinz Christoph Maeusli |
Independent Director |
08/04/2026 |
| Ms. Renee Aguiar-Lucander |
Independent Director |
08/04/2026 |
|
|
|
|